2012.Aug.08

未分類

Corporate

Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

HOMEWhat’s NewNewsBreast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2012.Jul.20

DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD

2013.Jan.18

OBI's company English name official renamed OBI Pharma, Inc.